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Abstract
Melanoma, which is the most malignant skin cancer type, has got one of the fastest
increasing incidence rates of all cancer types in the world. When belatedly diagnosed,
melanoma is extremely invasive and metastatic. Although there are effective drugs used
to treat melanoma, some cell lines have proven resistant to chemotherapy. In this con-
text, several research groups on natural products have investigated the anticancer effect
of new natural molecules in the treatment of melanoma. Flavonoids have shown to play
an important role in chemoprevention and inhibition of the proliferation, migration, and
invasion of melanoma cells. In this chapter, we present a systematic review performed
through a literature search over a period of 20 years, using specialized databases. Analysis
of all selected manuscripts demonstrated that at least 97 flavonoids have already been
investigated for the treatment of melanoma using in vitro or in vivo models. Most of the
bioactive flavonoids belong to the classes of flavones (38.0%), flavonols (17.5%), or
isoflavonoids (17.5%). Apigenin, diosmin, fisetin, luteolin, and quercetin were considered
as the most studied flavonoids for melanoma treatment. In general, flavonoids have
shown to be a promising source of molecules with great potential for the treatment of
melanoma.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Natural products have contributed significantly to new drugs discovery. Historically, natural
products derived from plants, microorganisms, and animals have been a promising source of
medicinal preparations and molecules with therapeutic potential, for various diseases, includ-
ing cancer treatment. The study of natural products also contributed to the provision of unique
chemical structures, which were chemically modified, resulting in the development of new
drugs [1–3].
An analysis of the new medicines approved by the US Food and Drug Administration (FDA)
between 1981 and 2010 revealed that 34% of those drugs were based on small molecules from
natural compounds or derivatives of natural compounds (semisynthetic products). This
includes drugs such as statins, tubulin-binding anticancer, and immunosuppressant drugs. In
this context, it is evident the contribution of natural products for drug discovery [3–5].
In the search for new anticancer drugs, natural products have provided many structural
models with different mechanisms of action, for the treatment of melanoma regional or distant
metastatic melanoma. Vinblastine from Vinca rosea and paclitaxel, which originates from a
Chinese plant, is an example of anticancer agent obtained from natural sources. The therapy
also includes drugs with different mechanisms of action, such as immunomodulatory agents,
BRAF, and MEK inhibitors, and most recently, use of vaccines [6, 7]. However, even with
recent advances in anticancer therapy, there is still a demand to develop new effective antican-
cer drugs for the melanoma treatment [8].
Despite the diversity of treatments for melanoma, the high resistance of tumor cells to conven-
tional therapies drives the search for new anticancer agents that have less toxic effects, and
greater effectiveness, incentive to develop new therapies that can be used individually or in
combination with other drugs bringing therapeutic benefits for the patient. The polyphenolic
compounds like flavonoids possess a large spectrum of pharmacological activity, including
anticancer activity. These secondary metabolites have molecular mechanisms of action in
tumor cells already understood, acting in enzymes and receptors associated and signal trans-
duction pathways relating to cellular proliferation, differentiation, apoptosis, inflammation,
angiogenesis, and metastasis [9–11].
2. Pathological aspects of skin cancer (melanoma)
2.1. Definition
Melanomas are malignant skin tumors deriving from melanocytes, the melanin-producing
cells, that typically occur in the skin but may rarely occur in mucous membranes (vulva,
vagina, and rectum), or uvea, the pigmented layer of the eye, lying beneath the sclera and
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cornea, and comprising the iris, choroid, and ciliary body. Melanomas account for less than 2%
of skin cancers but are responsible for 80% of the mortality of patients with skin cancer [12].
They are classified in several subtypes, according to their tissue origin, tumor form, spreading
and infiltrating behavior, metastatic potential, etc. These includes (a) superficial spreading
melanoma, that tend to start growing outwards rather than downwards into the skin, (b)
nodular melanoma, that tends to grow downwards, deeper into the skin, (c) lentigo maligna
melanoma, that develops from very slow growing pigmented areas of skin called lentigo
maligna or Hutchinson’s melanotic freckle, (d) acral lentiginous melanoma, most commonly
found on the palms of the hands and soles of the feet or around the big toenail, and (e)
amelanotic melanoma, that usually have no, or very little color, occasionally are pink or red,
or have light brown or gray around the edges [13].
2.2. Etiology
The precise etiology of melanoma depends on several individual factors and is probably
multifactorial in most cases [12]. Sun exposure (particularly UVB radiation) and genetic sus-
ceptibility (including faulty DNA repair) have been reported as major environmental and
genetic factors associated with the risk of melanoma initiation and promotion [14, 15]. Precur-
sor lesions, particularly dysplastic nevi/atypical moles, probably play a critical role in mela-
noma initiation [16]. Moreover, the distribution of melanoma among various work forces
suggests that occupational risk factors could play an important role in the etiology of this
cancer. For example, melanoma incidence is significantly higher in populations working in
printing and press, petrochemical, and telecommunications industries [17].
2.3. Progression
The development of a melanoma tumor is considered a multistage process that involves
various genetic and epigenetic alterations. From a histopathological point of view, the follow-
ing steps can be considered: (a) common acquired nevi and dysplastic nevi, (b) radial growth
phase melanoma, in which melanocytes undergo changes that enable them to survive and
proliferate (c) vertical growth phase melanoma, in which tumor cells deeply invade into the
dermis/hypodermis, and (d) malignant metastatic melanoma, in which the cells may eventu-
ally invade the endothelium and migrate to distant tissues [18–20]. When diagnosed in the
early stages, melanoma can be easily treated by surgical excision of the primary tumor [21].
However, when the disease is at an advanced stage the treatment is very difficult because the
cancer cells have a high capacity to cause metastases (including brain metastases) and acquire
resistance to conventional therapy [22, 23]. The progression of cutaneous melanoma in the skin
can be classified using the Clark method [18, 19] (Figure 1).
This classification is not very used, contrary to the TNM one, which is regularly revised by the
American Joint Committee on Cancer (AJCC) [24, 25]. The TNM classification is based on the
thickness of the primary tumor (T, also known as Breslow's index), presence of metastatic cells
in the neighboring lymph nodes (N), and localization of metastasis in the body (M) (Table 1).
The T criterion is subdivided into four categories from T1 to T4 discriminating melanomas
from 1 –4 mm thick. Each category is subdivided into two subgroups that report the presence
(a) or not (b) of ulceration of the primary tumor. The survival rate decreases with an increase in
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Figure 1. Progression stages of the cutaneous melanoma, according to the Clark skin infiltration classification [18, 19].
Tclassification Tumor thickness Ulceration-mitosis
T1 ≤1.0 mm a. Without ulceration and mitosis < 1/mm2
b. With ulceration or mitosis ≥ 1/mm2
T2 1.01–2.0 mm a. Without ulceration
b. With ulceration
T3 2.01–4.0 mm a. Without ulceration
b. With ulceration
T4 >4.0 mm a. Without ulceration
b. With ulceration
N classification Metastatic lymph nodes Size of metastatic lymph nodes
N0 0 –
N1 1 a. Micrometastasis
b. Macrometastasis
N2 2–3 a. Micrometastasis
b. Macrometastasis
c. In transit without metastatic nodule
N3 ≥4 –
M classification Site Seric LDH
M0 0 –
M1a Subcutaneous tissue and/or metastatic lymph nodes Normal
M1b Lung metastasis
viscera metastasis
Normal
M1c Distant metastasis High
Table 1. The TNM classification of melanoma progression (adapted from Ref. [26]).
Natural Products and Cancer Drug Discovery164
the thickness of the tumor, which may, however, be smaller in the presence of ulceration. The
classification N evaluates the number of neighboring lymph nodes containing metastatic
melanoma cells. This criterion is subdivided into four categories from N0 to N3, as well as
three subgroups according to the presence of small metastases detected after biopsy (a), large
metastasis detected after clinical examination (b) and metastases in transit (c) (melanoma cells
located between the primary tumor and the lymph node region in lymph channels). The
classification M, with four categories from M0 to M1c, evaluates the localization of metastases
in the organism, as well as the increase in serum lactate dehydrogenase concentration [24].
According to the TNM parameters, four melanoma progression stages can be defined (Table 2).
The only efficient treatment is the early surgical resection of the primary melanoma, when
tumor cells have not already spread to nearby lymph nodes (stages I and II). Advanced and
metastatic melanoma (stages III and IV) has very poor prognosis as most chemotherapeutical
agents used to treat cancers are ineffective in killing melanoma cells, which are constitutively
or adaptively resistant to proapoptotic drugs [22]. Melanoma is also resistant to radiotherapy
[27, 28]. The overall positive responses to melanoma monotherapy using conventional antican-
cer drugs are weak and range from 4 to 26% [22]. Additionally, melanoma tumor displays
pronounced neoangiogenesis [29] and a high ability to escape immune cell that explain why
the 5-year survival rate for metastatic melanoma ranges from 5 to 10%, with a median survival
of less than 8 months [30, 31]. Brain metastasis is present in 75% of stage IV melanoma
patients, and constitutes a major cause of mortality because of the low permeability of the
blood-brain barrier to chemotherapeutic drugs [30].
2.4. Epidemiology
Since 2005, World Health Organization (WHO) has identified the cutaneous melanoma as a
priority public health concern as 132,000 new cases are registered every year in the world [32].
Since the early 1970s, the incidence of malignant melanoma has increased significantly, for
example an average 4% every year in the United States [12, 14, 33]. The melanoma death rate in
Stage T N M
I IA T1a N0 M0
IB T1b-T2a N0 M0
II IIa T2b/T3a N0 M0
IIb T3b-T4a N0 M0
IIc T4b N0 M0
III IIIa T1 to T4b N1a-N2a M0
IIIb T1 to T4a N1b-N2b-N2c M0
IIIc T1 to T4b N3 M0
IV - T1 to T4b N1 to N3 M1
Table 2. Melanoma progression stages based on the TNM classification (adapted from Ref. [26]).
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2012 was the highest in Australia and New Zealand (3.5/100,000) and Europe (2.3 per 100,000
people). In 2014, 76,100 new cases were diagnosed in the United States and 9710 patients with
cutaneous melanoma died, according to the American Cancer Society. The wide disparity in
melanoma incidence throughout the world depends upon the variation of early sun-exposure
behaviors, recreational and vacation histories, nevus phenotypes and skin phototypes, distri-
bution of melanoma risk genotypes, and discrepancies in epidemiological registrations
between countries [34]. According to the WHO, a large number of atypical nevi (moles) are
the strongest risk factor for malignant melanoma in fair-skinned populations. Malignant mel-
anoma is more common among people with a pale complexion, blue eyes, and red or fair hair.
It is over 20 times more frequent in White people compared to African-Americans and the risk
increases with the age, although it also affects young adults, especially women. High, inter-
mittent exposure to solar UV appears to be a significant risk factor for the development of
malignant melanoma [14, 35], particularly for White people living in tropical regions [36, 37].
The incidence of malignant melanoma in White populations generally increases with decreas-
ing latitude, with the highest recorded incidence occurring in Australia, where the annual rates
are 10 and over 20 times the rates in Europe for women and men, respectively. Several
epidemiological studies support a positive association with history of sunburn, particularly
sunburn at an early age [34]. The role of cumulative sun exposure in the development of
malignant melanoma is equivocal. However, malignant melanoma risk is higher in people
with a history of nonmelanoma skin cancers and solar keratoses, both of which are indicators
of cumulative UV exposure [38].
2.5. Immunity and immunotherapy of melanomas
Activation of genes in transformed melanocytes leads to the expression or overexpression of
tumour-associated antigens. Several melanoma-associated antigens (MAA) have been identi-
fied and classified according to their tissue expression and structure [39, 40]. These include
proteic antigens that can be recognized as MHC-I—peptide complexes by cytolytic T lympho-
cytes, membrane gangliosides, and conformational antigens inducing strong humoral
responses by B-lymphocytes. MAGE-1, 2, 3 and 4 antigens are expressed by metastatic
melanoma while their expression is absent in melanocytes and weak in primary melanoma
tumors, indicating that the corresponding genes are activated during malignant transforma-
tion and progression [41]. Other MAA such as Melan-A/melanoma antigen recognized by
T-cells (MART-1), tyrosinase, Pme117/gp100, gp75/tyrosine-related protein (TRP)-1 and AIM-2
are expressed in normally differentiated melanocytes and melanoma cells but absent in other
tumor cells, suggesting the possibility to target them for a specific destruction of melanoma
tumors [42, 43]. The expression of various gangliosides present in the membranes of melano-
cytes and melanoma cells (GM3, GD3, GM2, GD2 and O-acetyl GD3) is also significantly
increased during malignant transformation [44]. Given that malignant melanoma is one of the
most immunogenic tumor and that melanomas are highly resistant to chemotherapy and
radiotherapy, immunotherapy appears as one of the most promising and relevant strategies
to destroy melanoma tumors and metastatic cells.
Promising results have been reported using ex-vivo stimulation of tumor-infiltrating lympho-
cytes by cytokines and MAA, potentiation of T-cell cytotoxic activity by blocking CTL-A4
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co-inhibitory receptor (using monoclonal antibodies), CAR-T strategies, and combination of
immunotherapy with chemotherapeutics (e.g., dacarbazine/CTL-A4 blockade) [22, 31, 45–49].
Interferon-α and interleukin-2 monotherapeutic treatments give an overall positive response in
13–25% patients, and constitute a first-line therapy for nonmetastatic patients. Ipilimumab, an
anti-CTLA-4 monoclonal antibody, targeting a T-cell receptor decreasing T-cell activation and
cytotoxicity, allows a long-term survival benefit in one-third of metastatic melanoma patients,
and a complete remission in patients [50]. As a consequence, a high research effort is dedicated
to the development of new antibodies activating antitumoral immunity and to the discovery of
new natural drugs with cytostatic, antimetastatic, and/or antiangiogenic activity that could
stimulate the immune system and be used in chemoimmunotherapy protocols to synergize
with chemotherapeutic drugs and immune effectors.
In this view, only a few natural molecules have proved their efficacy to limit tumor growth and
inhibit the invasiveness of highly aggressive melanoma cells in in vitro and in vivo models. The
efficacy of such molecules is related to their antiangiogenic activity (e.g., resveratrol [51],
curcumin [52]), to their capacity to induce melanoma cell death regardless of their apoptosis-
sensitivity (e.g., narciclasine [53], carotenoids [54–59]), to their ability to target components of
apoptotic pathways to overcome melanoma cells resistance to anticancer drugs (e.g., epigallo-
catechin gallate [60–62]), or to their strong stimulatory effect on antitumoral immunity (e.g.
Lentinula edodes polysaccharides [63]). Considering the clinical efficacy of melanoma immuno-
therapy, combined to the high potential of natural compounds to limit melanoma growth and
restore melanoma sensitivity to apoptosis inducers without impairing antitumoral immunity,
an important research effort should be undertaken to assess the efficacy of original natural
cytostatic compounds, highlight the molecular and cellular mechanisms involved in their
pharmacological action, and study if these molecules favor in vivomelanoma rejection via their
immune regulatory properties. Considering the fast growth of melanoma and failure of cur-
rent treatments, the identification and clinical development of such efficient molecules will
obviously have a significant impact on patient survival rate and duration.
3. Molecular and cellular pathways involved in melanoma biogenesis and
progression
3.1. Implication of the MAPK pathway
The receptor tyrosine kinase MAPK pathway triggers a signaling cascade that regulates cell
growth, proliferation, differentiation, and survival in response to a wide variety of extracellu-
lar stimuli including hormones, cytokines, and growth factors through the activation of tyro-
sine kinase receptors. As mutations of components of the MAPK pathway are associated with
increased activity of ERK1/2 proteins [64], deregulation of this pathway contribute to both
development and progression of melanoma. In particular, mutations in B-RAF, a member of
the RAF kinase family, have been identified in up to 70% of malignant melanoma [65].
Binding of a ligand to the membrane bound tyrosine kinases receptors (RTKs) or integrins
adhesion to extracellular matrix triggers the activation of the RAS GTPases which further lead
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to activation/transduction of the MAPK signaling pathway. Ras GTPases are small proteins
bound to the cytoplasmic membrane. The RAS gene encodes three isoforms with tissue-
specific pattern: HRAS, KRAS, and NRAS [64]. Downstream targets of RAS proteins are the
PI3K/Akt pathway and the serine threonine kinase RAF proteins [66, 67]. Activated B-RAF
then leads to the activation of the MEK/ERKs kinases, which targets a variety of signaling
pathways such as cell growth, proliferation, protein synthesis, and apoptosis.
The RAF kinase family consists of three cytoplasmic proteins (A-RAF, B-RAF, and C-RAF)
which participate in the MAPK transduction pathway. Unlike, c-RAF and A-RAF, mutations in
B-RAF have been identified in up to 70% of malignant melanoma [68, 65]. Most frequent
activating somatic mutations in B-RAF occur at the V599E where a valine replaces a glutamic
acid [68]. Identification of such activating mutations in B-RAF proteins leads to the develop-
ment of new drugs, such as B-RAF inhibitors, as anticancer strategies [69].
These oncogenic B-RAF proteins are able to transform fibroblastic cell line and lead to
hyperactivation of the ERK proteins [68]. Constitutive ERK leads to increased proliferation
apoptosis resistance in melanoma cells [69]. Interestingly, suppression of the tumor suppressor
PTEN and activating mutations in B-RAF are both necessary in melanoma development
highlighting the importance of the PI3K/Akt pathway upregulation in melanoma growth and
apoptosis resistance [70].
Indeed, the tumor suppressor PTEN is downregulated in melanoma and this is associated with
PI3K/Akt hyperactivation [71]. Apoptosis resistance could be mediated through activation of
the NF-KB pathway, target of hyperactive ERK proteins [72]. Oncogenic B-RAF also leads to
inhibition of the LKB1-AMPK pathway, a central signaling pathway at a crossroad between
metabolism and proliferation regulation through, in particular, inhibition of the mTOR path-
way. This study highlights a new pathway in tumor growth regulation [73]. Finally, expression
of MCL-1, a member of the Bcl-2 pathway, whose alternative splicing leads to proteins with
either pro- and antiapoptotic activities, is increased in melanoma metastasis associated with
oncogenic B-RAF [74]. Oncogenic B-RAF may also trigger the antiapoptosis pathway through
inhibition of the proapoptotic Bim proteins [75].
Besides, downregulation of a downstream target of the MAPK pathway, MITF (microphthalmia-
associated transcription factor), the master regulator of melanocyte development, survival, and
function, is associated with poor diagnosis and melanoma progression [76]. Finally, cKIT, a
tyrosine kinase receptor, might trigger proliferation signals in melanoma through activation of
the MAPK pathway [77].
Others signaling pathways contribute to melanoma progression and metastasis such as the
noncanonical Wnt signaling [78] and deregulation of the cyclin-dependent kinase inhibitor 2A
(CDKN2A) pathway involved proliferation and apoptosis control [23].
3.2. Implication of extracellular vesicles (EV) in melanoma biogenesis and progression
Extracellular vesicles (EVs) are small vesicles released by most cell types in the extracellular
environment, and as a consequence can be retrieved from various body fluids, especially
plasma. EV might split into apoptotic bodies (>1 μm), microparticles (100 nm to 1 μm) released
after membrane blebbing and exosomes (<100 nm), vesicles with an endosomal origin release
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after multivesicular bodies fuse with the plasma membrane [79]. EVs are biological vectors
that convey lipids, different classes of proteins (cytoskeleton, adhesion, raft associated pro-
teins, histones, chaperones [80], glycoproteins, and chemokines [81] or even morphogens such
as Hedgehog proteins [82]. EVs also harbor nucleic acids [83] able to modulate the differenti-
ation of the target cells [84]. EVs communicate with their target cells via receptor-ligand
interaction, through transfer of membrane proteins [85, 86], can fuse with the plasma mem-
brane [87], or transfer their components into target cells via phagocytosis [88] or endocytosis
[89]. The ability of EVs released from antigen presenting cells to convey MHC class II proteins
[90] highlights their immunomodulatory properties and their potential as therapeutic agents in
anticancer strategies [91]. Moreover, as they carry tumor antigens via MCH class I proteins,
EVs can initiate antitumor response in vitro [92] and in vivo [93]. Nevertheless, the composition
of EVs and the message they convey depend both on the cells they originate from and the
conditions triggering their release. Indeed, EVs from dendritic cells can also suppress immune
response in inflammatory diseases models such as DTH (delayed-type hypersensitivity) mice
[94]. This ability to attenuate immune response might be associated with the capacity of EV to
induce expression of molecules able to inactivate T-cells or suppress immune response [95].
In addition to their immunomodulatory properties, the role of EVs in inflammation, angiogen-
esis, and proliferation has been widely demonstrated [96–98]. This suggests an implication for
EVs in tumor survival and progression. In this study, exosomal markers, such as CD63, could
be found also on a wide range of subpopulations of EVs, and as long as there is no determina-
tion of the cellular origin of vesicles, we chose to use the term EV to refer to both exosomes and
microparticles.
3.3. Role of circulating EV in melanoma biogenesis and progression
Circulating EV can trigger inflammatory pathways in target cells [96], stimulate angiogenesis
[82, 99, 100], protect against apoptosis [101], or stimulate proliferation [102].
Plasma levels of EV harboring CD63 in melanoma-engrafted SCID mice correlate to tumor
size, suggesting a role of the tumor in EV secretion [103]. However, other suggests that
circulating rates of EV do not differ between melanoma and healthy patients [104–106] but
instead, EV protein composition might differ. In particular, plasmatic EVs from melanoma
patients are enriched in platelet-derived EV involved in neovascularization (CD42a harboring
EV) and antitumour immune responses (CD8 harboring EV) [105]. Furthermore, circulating
endothelial and platelet derived-EV (EEV) and procoagulant EV are significantly higher in
melanoma patients [107]. Such procoagulant EVs stimulate proinflammatory cytokines secre-
tion by macrophages and drive melanoma metastasis in vivo [108] reinforcing the implication
of EV in melanoma progression.
3.4. A role of EV in melanoma metastasis
EV release is exacerbated in human malignant [109] and murine [110] melanoma cell lines.
Furthermore, in comparison with murine melanocyte cell line, metastastic melanoma cell lines
secrete highly procoagulant EV harboring phosphatidylserine and enriched in tissue factor pro-
teins suggesting that melanocyte transformation into cancer cells is associated with the secretion
of such EVs [110]. Besides, Wnt5a, a noncanonical Wnt signaling ligand in involved melanoma
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progression [78] induces the release of melanoma exosomes enriched in proangiogenic proteins
and pro-inflammatory cytokines [111].
Proteomic analysis of human malignant melanoma cell lines A375 reveals an enrichment in
proteins involved in angiogenesis and matrix remodeling such as annexin A1 and hyaluronan
and proteoglycan link protein 1 (HAPLN1) [109]. Analysis of EV microRNA content reveals
enrichment in miRNA involved in cell growth, proliferation, and apoptosis. Uptake of such EV
promotes the invasion ability of normal melanocytes [109]. Furthermore, tumor-derived EV
harbor FAS ligand involved in antitumor response through lymphocytes apoptosis [112]. Finally,
human (SK-Mel28/-202/-265/-35) andmouse (B16-F10) cell line–derived exosomes are enriched in
TYRP2 (tyrosinase-related protein-2), VLA-4 and Hsp90 proteins. Indeed, B16F10-derived
exosomes are enriched in prooncogenic proteins such as the oncogene MET which has been
described a role in cell transformation, proliferation, survival, invasion, and metastasis [113–
115]. BM cell treatment with such exosomes led to an increase in tumor size compared to
nontreated mice. Compared to EV derived from B16F1, a poor metastatic cell line, injection of
B16F10 EV led to increased metastatic lesions and a wider tissue distribution (brain, bone) [106].
This is in agreement with previous studies suggesting that highly metastasis cells are enriched in
oncogene Met72 and are more deleterious than B16F1-derived EV [116]. These data strongly
suggest that EV from melanoma cells is able to suppress antitumor response and stimulate
tumor progression but also their ability to trigger melanoma invasion and metastasis. However,
different populations of EV have distinct procoagulant properties [117]. Thus, it is therefore
necessary to identify the cell origin of EV in order to determine their role in cancer progression.
3.5. Role of microRNAs in melanoma progression
MicroRNAs are noncoding small RNAs able to bind target mRNAs, through their 30UTRs
leading to their degradation. Binding of microRNAs to their targets allows regulating a wide
variety of cellular mechanisms such as proliferation, angiogenesis, inflammation, and survival.
A role for microRNAs in melanoma progression was first demonstrated through different
miRNA expression signatures associated with the developmental lineage and differentiation
state of solid tumors [118]. Furthermore, a microarray analysis demonstrates a specific
targeting between A375 cell line and the A375 cells-derived EV of 28 miRNAs involved in
cellular growth, development, and proliferation [109]. Relevance of microRNAs implication in
melanoma development was illustrated by the fact that miRNAS loci are retrieved in genomic
regions altered in melanoma [119]. MITF (microphthalmia-associated transcription factor) the
master regulator of melanocyte development, survival, and function, which is often
dysregulated in melanoma is a target of miR-137 [120] and miR-182 [121]. Finally, a number
of microRNAs such as miR-214 [122] and miR-223 [123], but also miR-137, miR-182, miR-221/
222, and miR-34a, have been involved in melanoma progression (for a review see [124]). In
particular, miR-221 and miR-222 are involved in tumor proliferation and an increased in
invasion and migration abilities through targeting of p27Kip1/CDKN1B (cyclin-dependent
kinase inhibitor 1B) and the tyrosine kinase receptor c-KIT receptor [124, 125].
However, five members of the Let-7 family are downregulated in primary melanoma suggesting
that these microRNAs might trigger anticancer responses. In particular, Let7b which targets
cyclins exerts antitumoral responses through inhibition of cancer cycle progression [126].
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MicroRNAs can also be transported via EV and regulate the pathway in distant target cells. In
particular, circulating EV from metastatic melanoma patients harbors a specific miRNA signa-
ture. Indeed, those EVs are enriched in oncogenics miRNAs mir17 and miR19a suggesting a
role for miRNAs-associated EV in tumor progression and metastasis [127]. On the other hand,
circulating EV in advanced melanoma patients shows a decrease in miR-125b which
downregulation has been described in melanoma progression [128].
Finally, deep-RNA sequencing allows identifying an enrichment of 23 specific microRNAs in
small EV including miR-199a-3p, miR-150-5p, miR-142-3p, and miR-486-5p known to be
involved in melanoma progression or identified in melanoma metastasis or patient blood sam-
ples [129]. In particular, miR-214 has been associated with melanoma metastasis [122]. Interest-
ingly, in silico analysis reveals that some of these miRNAs could target the BRAF pathway which
is often deregulated in melanoma [129]. Metastatic cell lines secrete EVenriched in the oncogenic
miR-222. Furthermore, miR-222 associated with EV can be transferred into target cells and
promote tumorigenesis through activation the Akt/PI3K pathway [130].
3.6. Identification of new markers for melanoma diagnosis and prognosis
Circulating concentrations of lactate dehydrogenase [79], S100 and MIA (Melanoma Inhibitory
Activity), two small proteins expressed by melanoma cells, are significantly higher in melanoma
patients [131] and thus are widely used a proteins markers in order to monitor melanoma
progression. LDH concentrations might be a better prognosis factor to classify advanced mela-
noma [132, 133].
Other circulating factors such as circulating nucleic acids or EV could be used in melanoma
detection as a prognosis factor in advanced stages of diseases. Indeed, circulating EVs from stage
III to stage IV are enriched TYRP2 (tyrosinase-related protein-2), a specific melanoma protein,
VLA-4 (very late antigen 4) and HSP90. Furthermore, these enriched EVs correlated with poor
survival prognosis [106]. These authors identified a specific exosomes protein signature that
could be used as a prognosis marker in stages III and IV melanoma patients [106].
Besides, circulating EV carries melanoma markers such as S100B and MIA proteins. Concentra-
tions of EV-S100B and EV-MIA are higher in stage IV melanoma patients and such EV was
associated to poor prognosis in patients [104]. Detection of such EV could be used as an additional
diagnosis and prognosis marker of melanoma patients. In contrast, these authors did not find an
increase in TYRP2 containing exosomes in plasma of melanoma patients. This discrepancy could
be due to difference in EV isolation, or EV concentrations/number analysis (NTA analysis vs. EV-
protein concentration determination). Finally, circulating EV enriched in oncogenes miRNAs
mir17 andmiR19a could be used as predictivemarkers inmelanomapatients [127].
In addition, some microRNAs detected in patient metastasis such as miR-150, miR-342-3p, miR-
455-3p, miR-145, miR-155, and miR-497 could be used as a specific signature to predict
postsurvival recurrence with a high expression of miR-145, miR-155 in metastatic tissue associ-
ated with longer survival [134]. Finally, identification of a specific signature of 16 differentially
expressed microRNAs in patient blood samples represents a new noninvasive tool in diagnosis
applications [135]. Finally, other authors suggest that microRNAs from blood patients could be
used to monitor melanoma recurrence [136, 137].
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4. Current melanoma treatment
The treatment options for regional or distant metastatic melanoma have expanded in recent
years and are directly influenced by disease stage at diagnosis and the extent of metastases.
The therapy used includes several drugs with different mechanisms of action, including
chemotherapies, immunomodulatory agents, the serine/threonine protein kinase BRAF, mito-
gen-activated protein kinase (MEK) inhibitors, and most recently, use of vaccines [6, 7]. The
primary treatment of this cancer type is surgical excision, sentinel lymph node dissection,
radical lymph node dissection, and isolated limb perfusion [138, 139].
Chemotherapy may now be considered a second or third line in patients with resistance to
immunotherapy and targeted therapy [140]. Tumor cells may evade the immune attack by
some mechanisms, such as impaired antigen presentation, expression of factors with immuno-
suppressive properties, such as transforming growth factor-beta (TGF-β), vascular endothelial
growth factor (VEGF), interleukin-2 (IL-2), and induction of resistance to apoptosis. In addi-
tion, melanoma cells further express receptors on the cell surface which function as check-
points to the immune system response, as the cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) and programmed cell death protein 1 (PD-1). The ipilimumab is an anti-CTLA-4
monoclonal antibody and the nivolumab and pembrolizumab are also monoclonal antibodies
directed against the PD-1 receptor, that blocking the inhibitory ligand's suppression of
immune response. Thus, the main objectives of immunotherapy are to activate an immune
response through the immunostimulation of IL-2, the upregulation of tumor-inhibitory T cells,
and the inhibition of the immune control points [141, 142].
In addition to the immunological approach, targeted therapies have also been employed in the
treatment of melanoma, such as BRAF and MEK inhibitors. The BRAF gene is responsible for
encoding the B-raf protein that participates in the regulation of the mitogen-activated protein
kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway, which regulates
cell proliferation, differentiation, and cell cycle progression [142]. The discovery that BRAF
was mutated in about 50% of melanomas led to the development of BRAF kinase inhibitors as
vemurafenib and dabrafenib. However, most patients acquire resistance mechanisms to BRAF
kinase inhibition [141, 143]. In view of the development of resistance to single BRAF blockade,
several combination schemes have been developed, as the combination therapy with MEK
inhibitors trametinib and cobimetinib [144–146].
Despite these advances, about 80% of patients develop resistance to the current standard of
treatment with the combination of a selective BRAF and MEK inhibitors, which stimulates
research for new treatment alternatives. The use of triple combining therapy has also been the
subject of investigations and demonstrated prolonged responses [147]. Preclinical assays
performed with the triple combination of BRAF and MEK inhibitors and anti-PD-1 demon-
strated high antitumor activity and phase I/II clinical studies have shown promise in
BRAFV600-mutated melanoma [148]. Moreover, vaccines have also been investigated and in
2015 the Food and Drug Administration (FDA) approved the Talimogene laherparepvec
(T-VEC), an oncolytic virus derived from herpes simplex type 1, which can selectively replicate
within tumors and produce granulocyte macrophage colony stimulating factor (GM-CSF)
which promotes increased antitumor immune response [149].
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5. Chemical and biological aspects of flavonoids
Flavonoids are phenolic constituents commonly found in a variety of fruits, vegetables, and
medicinal plants. They add color, flavor, and aroma to plants, and play an important role in
protection mechanisms against pathogens, ultraviolet radiation, and herbivores. Flavonoids
comprise an important class of secondary metabolites, with numerous possibilities of chemical
structures [150, 151].
Flavonoids have a basic phenylbenzopyrone skeleton (C6-C3-C6), admitting several substitu-
tion possibilities. In accordance with the substitution pattern of A, B, and C rings of the basic
structure, flavonoids can be classified as chalcones, aurones, flavones, flavonols, flavanols,
flavanones, isoflavones, flavanonols, among others [10]. The most common classes of flavo-
noids are shown in Figure 2.
Flavonoids may include the polyhydroxylated or polymethoxylated form. There are more than
8000 flavonoids identified, some of the most abundant are quercetin, catechin, and kaempferol,
which are often combined with glycosidic units (commonly glucose, galactose, and rhamnose)
through C-C or C-O-C bonds [152, 153]. The structural diversity of flavonoids directly influ-
ences their chemical, physical and pharmacological properties.
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Figure 2. Basic skeleton (C6-C3C6) and main classes of flavonoids. This figure was adapted from Ref. [10].
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Several studies have demonstrated the therapeutic properties of flavonoids obtained from plants
or through synthesis. In fact, the structural diversity of flavonoids contributes to the diverse
pharmacological activities reported for these compounds. In vitro and in vivo assays have shown
the antioxidant, anti-inflammatory, antinociceptive, cardioprotective, photoprotective, antide-
pressant, antimicrobial, and cytotoxic effects of flavonoids [154, 155].
Recently, flavonoids have been shown to be potent antitumor agents. These compounds
showed promising effect against different tumor cell lines, including human melanoma cells
[156, 157]. In addition, flavonoids typically exhibit low toxicity in biological systems, which
make them an alternative therapy compared with traditional anticancer drugs [158–161].
6. Bioactivity of flavonoids on melanoma
In this section, the authors present a systematic review performed through a literature search
over a period of 20 years (January 1996–December 2016). This literature search was performed
through specialized databases (PUBMED, LILACS, SCIELO, Science Direct, and Web of Sci-
ence) using different combinations of the following keywords: flavonoid, flavonoid derivative,
melanoma, skin cancer, treatment, and anticancer therapy. We did not contact investigators
and we did not attempt to identify unpublished data.
Manuscripts were selected based on the inclusion criteria: articles published in English, Portu-
guese, Spanish, or French and articles with keywords in the title, abstract, or keywords, as well
as studies involving anticancer activity of natural flavonoids necessarily against melanoma in
in vitro or in vivo models. Other review articles, meta-analysis, abstracts, conferences, editorial/
letters, case reports, conference proceedings, or articles that did not meet the inclusion criteria
were excluded from this systematic review.
For the selection of the manuscripts, two independent investigators (RGOJ and CAAF) first
selected the articles according to the title, then to the abstract, and finally through an analysis of
the full-text publication. A consensus between the investigators was reached as a clarification for
in order to clarify all disagreements. The selected articles were manually reviewed with the
purpose of identifying and excluding the works that did not fit the criteria described above.
The primary search identified 164 articles. However, among these, 39 manuscripts were indexed
in two or more databases and were considered only once, resulting in 125 articles. After an initial
screening of titles, abstracts, full text, and time of publication, 43 articles were selected, while the
remainder did not meet the inclusion criteria (n = 82). Although many articles presented prom-
ising anticancer activity for plant extracts rich in flavonoids, we considered only articles that
showed anticancer activity of the isolated flavonoids on melanoma cell lines. Investigations
involving synthetic flavonoids were also excluded from this review. A flowchart illustrating the
progressive study selection and numbers at each stage is shown in Figure 3.
Analysis of all selected manuscripts demonstrated that at least 97 flavonoids have already
been investigated for the treatment of melanoma using in vitro or in vivo models. Most of the
bioactive flavonoids belong to the classes of flavones (38%), flavonols (17.5%), or isoflavonoids
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(17.5%), which has aroused the interest of several research groups in natural and synthetic
products in the world. All information about these flavonoids for the treatment of melanoma
was reported in Box 1. Next, we highlight the anticancer properties of the main tested flavo-
noids on melanoma cells (apigenin, diosmin, fisetin, luteolin, and quercetin).
6.1. Bioactivity of apigenin on melanoma
Apigenin (40,5,7,-trihydroxyflavone) is a nonmutagenic and low-toxicity dietary flavonoid
commonly present in many fruits, vegetables, and medicinal plants. This flavone has a broad
spectrum of antiproliferative activities against many types of cancer cells, including mela-
noma. Recent studies have demonstrated that apigenin inhibits cell growth through cell cycle
arrest and apoptosis in malignant human melanoma cell lines. Hasnat et al. [169] showed that
treatment with 50 μM apigenin significantly reduced viable cell percentages in A375 and
A2058 human melanoma cells. Treatment with apigenin for 24 h also decreased human mela-
noma cell numbers in a dose-dependent manner. A similar result was observed by Spoerlein
et al. [170], who evaluated the cytotoxic potential and the effect of apigenin on the cell cycle of
518A2 human melanoma cells. Apigenin also caused a dose-dependent decrease in the per-
centage of transwell-migrated cells, and ∼90 and ∼70% inhibitions of cell migration were
recorded upon treatment with 20 μM of apigenin, respectively, for A2058 and A375 cells [169].
The cytotoxic effects of apigenin were related to its ability to reduce integrin protein levels and
inhibit the phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated
kinase (ERK1/2). Furthermore, apigenin treatment increased apoptotic factors such as caspase-3
and cleaved poly(ADP-ribose) polymerase in a dose-dependent manner. Cao et al. [172] have
also demonstrated that apigenin suppressed STAT3 phosphorylation, decreased STAT3 nuclear
localization, and inhibited STAT3 transcriptional activity. Apigenin also downregulated STAT3
target genes MMP-2, MMP-9, VEGF, and Twist1, which are involved in cell migration and
invasion. In this same investigation, it was determined the in vivo antimetastatic effect of
Total of articles
(n = 164)
Exclusion of repetitions
(n = 39)
Screening of articles
(n = 125)
Articles selected for systematic review
(n = 43)
Articles did not meet the 
inclusion criteria (n = 82)
Figure 3. Flowchart of included studies for the systematic review.
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
Aurones
2,6-Dihydroxy-2-[(4-
hydroxyphenyl)methyl]-3-
benzofuranone
In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Anthocyanins
Cyanidin-3-O-β-
glucopyranoside (C-3-G)
In vitro M14 (HM) 5 or 10 μM A treatment with a single dose of
C-3-G decreased cell proliferation
without affecting cell viability
and without inducing apoptosis
or necrosis. C-3-G treatment also
induced increase of cAMP levels
and upregulation of tyrosinase
expression and activity resulting
in an enhanced melanin synthesis
and melanosome maturation.
Upregulation of the melanoma
differentiation antigen Melan-A/
MART-1 in treated cells respect to
the untreated control was
recorded.
[163]
Biflavonoids
Pteridium III In vitro A375 (HM) ND Preliminary test determined IC50
equal to 106.7 μM.
NE [164]
Chalcones
20,40-Dihydroxychalcone In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 44.3 μM.
NE [162]
4,40-Dihydroxy-20-
methoxychalcone
In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 56.3 μM.
NE [162]
Isoliquiritigenin (ISL) In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 80.5 μM.
NE [162]
In vitro
and
in vivo
(mice)
B16F0 (MM) 5–25 μg/ml A significant concentration- and
time-dependent reduction in cell
proliferation was observed. The
cell inhibition rate ranged from 18
to 79% and 35 to 91% after 24 and
48 h of ISL treatment (5, 10, 15, 20,
and 25 μg/mL), respectively. ISL
ISL increased reactive oxygen
species (ROS) formation during
B16F0 cell differentiation, but no
specific target was evaluated.
[165]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
did not show significant activity
in the in vivo model.
Phloretin In vitro M14 (HM) 1–40 μM Cell viability was 31.6% in M14
cells exposed to 40 μM of this
compound. Phloretin induced
apoptosis in a concentration
dependent manner with
significant effect at 20 μM after
48 h of treatment.
NE [166]
α,20,4,40-
tetrahydroxydihydrochalcone
In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Flavones
5,30 ,40-Trihydroxy-6,7,50-
trimethoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 14 μM.
NE [167]
5,40-Dihydroxy-6,7,30,50-
tetramethoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 241 μM.
NE [167]
5,6,30-Trihydroxy-7,40-
Dimethoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 18 μM.
NE [167]
5,6,40-Trihydroxy-7,30,50-
trimethoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 39 μM.
NE [167]
5,6,7-Trihydroxybaicalein In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 11 μM.
NE [167]
5,6-Dihydroxy-7,30 ,40-
trimethoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 29 μM.
NE [167]
5,7-Dihydroxy-6-
methoxyhispidulin
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 67 μM.
NE [167]
5,7-Dihydroxy-7-
methoxyflavone
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 119 μM.
NE [167]
6-Hydroxyluteolin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 13 μM.
NE [167]
6-Methoxyflavone In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 398 μM.
NE [167]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
6-Prenylapigenin In vitro B16 (MM) ND Preliminary test determined IC50
equal to 32.5 μM.
NE [168]
Albanin In vitro B16 (MM) ND Preliminary test determined IC50
equal to 84.7 μM.
NE [168]
Apigenin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 26 μM.
NE [167]
In vitro A375 and
A2058 (HM)
0–50 μM Treatment with 50 μM apigenin
significantly reduced viable cell
percentages in both types of
melanoma cells. Apigenin
exhibited dose-dependent
inhibition of melanoma cell
migration, unlike untreated
controls.
Apigenin reduced integrin
protein levels and inhibited the
phosphorylation of focal adhesion
kinase (FAK) and extracellular
signal regulated kinase (ERK1/2).
Furthermore, apigenin treatment
increased apoptotic factors such
as caspase-3 and cleaved poly
(ADP-ribose) polymerase in a
dose dependent manner.
[169]
In vitro 518A2 (HM) ND Preliminary test determined
IC50 > 50 μM. The flavonoid also
reduced cell migration.
Apigenin induced an arrest of the
cell cycle of 518A2 melanoma
cells at the G2/M transition and
also attenuated the expression
and secretion of the metastasis
relevant matrix
metalloproteinases MMP-2 and
MMP-9.
[170]
In vitro MDA-MB-
435 (HM)
1–50 μM Preliminary test determined
IC50 > 50 μM.
NE [171]
In vitro
and
in vivo
(mice)
B16F10
(MM), A375
and G361
(HM)
0–40 μM (in vitro tests) and
150 mg/kg (in vivo tests)
Apigenin (5 and 10 μM) also
dose-dependently inhibited
B16F10, A375 G361 cell migration
and invasion. Apigenin-treated
mice had significant fewer
metastatic nodules.
Apigenin suppressed STAT3
phosphorylation, decreased
STAT3 nuclear localization and
inhibited STAT3 transcriptional
activity. Apigenin also
downregulated STAT3 target
genes MMP-2, MMP-9, VEGF and
Twist1, which are involved in cell
migration and invasion.
[172]
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Artocarpin In vitro B16 (MM) ND Preliminary test determined IC50
equal to 10.3 μM.
NE [168]
Baicalein In vitro B16F10
(MM)
0–200 μM Treatment with 40 μM baicalein
resulted in approximately 87%
inhibition of cell growth.
Baicalein also inhibited the
migration and invasion of B16F10
cells.
Baicalein reduced the expression
of MMPs and tightening TJ
through the suppression of
claudin expression, possibly in
association with a suppression of
the phosphoinositide 3-kinase/
Akt signaling pathway.
[173]
In vitro B16F10
(MM)
3.156–50 μM Preliminary test determined IC50
equal to 50 μM.
NE [174]
Brosimone I In vitro B16 (MM) ND Preliminary test determined IC50
equal to 10.7 μM.
NE [168]
Chrysin In vitro 518A2 (HM) ND Preliminary test determined IC50
> 50 μM. The flavonoid also
reduced cell migration.
Apigenin induced an arrest of the
cell cycle of 518A2 melanoma
cells at the G2/M transition and
also attenuated the expression
and secretion of the
metastasisrelevant matrix
metalloproteinases MMP-2 and
MMP-9.
[170]
In vitro B16BL6
(MM)
ND Preliminary test determined IC50
equal to 20.5 μM.
NE [175]
In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 51 μM.
NE [167]
Cirsilineol In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 73 μM.
NE [167]
Cirsiliol In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 9 μM.
NE [167]
Cudraflavone B In vitro B16 (MM) ND Preliminary test determined IC50
equal to 12.5 μM.
NE [168]
Cudraflavone C In vitro B16 (MM) ND Preliminary test determined IC50
equal to 9.2 μM.
NE [168]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
Desmethoxylcentaureidin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 64 μM.
NE [167]
Diosmin In vivo
(mice)
B16F10
(MM)
0.2% solution (ad libitum as
drink)
Animals treated with diosmin
presented a reduction in the
number of subpleural mestases in
comparison to the negative
control group.
NE [176]
In vivo
(mice)
B16F10
(MM)
551 mg/kg/day Diosmin alone
or combined with different
doses of IFN-α
IFN-α showed a dose-dependent
antiinvasive and antiproliferative
activity in our study, while
diosmin showed an antiinvasive
activity similar to the lower dose
of IFN-α used. Combination of
diosmin and IFN-α have shown
synergistic effect.
NE [177]
In vivo
(mice)
B16F10
(MM)
0.2% solution (ad libitum as
drink)
Group treated with diosmin
showed the greatest reduction
(52%) in the number of metastatic
nodules.
NE [178]
In vivo
(mice)
B16F10
(MM)
20 mg/day Diosmin decreased the number of
metastatic nodules (52%),
implantation (79%), growth (67%)
and invasion (45%) index.
NE [179]
Eupafolin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 16 μM.
NE [167]
Eupatilin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 58 μM.
NE [167]
In vitro B16F10
(MM)
104–108 M Preliminary test determined IC50
from 33 to 85 μM.
NE [180]
Eupatorin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 44 μM.
NE [167]
Isolinariin A In vitro C32 (HM) ND Preliminary test determined IC50
equal to 11.76 μM.
NE [181]
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Isolinariin B In vitro C32 (HM) ND Preliminary test determined IC50
equal to 21.47 μM.
NE [181]
Jaceosidin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 27 μM.
NE [167]
In vitro B16F10
(MM)
104 to 108 M Preliminary test determined IC50
from 32 to 49 μM.
NE [180]
Kuwanon C In vitro B16 (MM) ND Preliminary test determined IC50
equal to 14.2 μM.
NE [168]
Linariin In vitro C32 (HM) ND Preliminary test determined IC50
equal to 12.6 μM.
NE [181]
Luteolin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 21 μM.
NE [167]
In vitro MDA-MB-
435 (HM)
1–50 μM Preliminary test determined IC50
equal to 30.3 μM.
NE [171]
In vitro A375 (HM) 0–80 μM Preliminary test determined IC50
equal to 115.1 μM. Luteolin also
inhibited colony formation and
induced apoptosis in a dose and
time-dependent manner by
disturbing cellular integrity as
evident from morphological
evaluation.
Accumulation of cells in G0/G1
(60.4-72.6%) phase for A375 cells
after 24 h treatment indicated cell
cycle arresting potential of this
flavonoid, but no specific target
was investigated.
[182]
In vitro B16F10
(MM)
3.156–50 μM Preliminary test determined
IC50 > 50 μM.
NE [174]
In vitro A2058 (HM) 0–80 μg/ml Luteolin inhibited cell
proliferation (IC50 = 35 μg/ml)
and increased apoptotic body
formation. Luteolin induces
apoptosis by Endoplasmic
Reticulum (ER) stress via
increasing Reactive Oxygen
Species (ROS) levels.
Luteolin increased expression of
the ER stress-related proteins;
protein kinase RNA-like ER
kinase, phosphor eukaryotic
translation initiation factor 2α,
activating transcription factor
(ATF) 6, CCAAT/enhancer-
binding protein-homologous
protein (CHOP), and cleaved
caspase 12. Furthermore, luteolin
[183]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
increased the level of intracellular
ROS, leading to ROS mediated
apoptosis and ER stress.
In vitro
and
in vivo
(mice)
B16F10 5–50 μM (in vitro tests) and
10–20 mg (in vivo tests)
Luteolin suppressed the hypoxia-
induced changes in the cells in a
dose-dependent manner. In
experimental metastasis model
mice, treatment with luteolin
reduced metastatic colonization
in the lungs by 50%.
Luteolin inhibited the hypoxia-
induced epithelial-mesenchymal
transition in malignant melanoma
cells both in vitro and in vivo via
the regulation of β3 integrin.
[184]
Morin In vitro B16 (MM) ND Preliminary test determined IC50
equal to 170 μM.
NE [168]
Norartocarpin In vitro B16 (MM) ND Preliminary test determined IC50
equal to 7.8 μM.
NE [168]
Pectolinarigenin In vitro B16F10
(MM)
ND Preliminary test determined IC50
equal to 64 μM.
NE [167]
Pectolinarin In vitro C32 (HM) ND Preliminary test determined IC50
equal to 7.17 μM.
NE [181]
Tangeretin In vivo
(mice)
B16F10
(MM)
20 mg/day Tangeretin decreased the number
of metastatic nodules,
implantation, growth and
invasion index.
NE [179]
Flavanones
3,7-Dihydroxy-6-
methoxyflavanone
In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
3,7-Dihydroxyflavanone In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
7-Hydroxy-6-
methoxyflavanone
In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 equal to 6.7 μM.
NE [162]
7-Hydroxyflavanone In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 equal to 99.9 μM.
NE [162]
Alnustinol In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
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Artocarpanone In vitro B16 (MM) ND Preliminary test determined
IC50 equal to 122.2 μM.
NE [168]
Dihydrobaicalein In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Dihydrooroxylin A In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 equal to 72.6 μM.
NE [162]
Eriodictyol In vitro B16F10
(MM)
3.156–50 μM Preliminary test determined
IC50 > 50 μM.
NE [174]
Garbanzol In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Isoxanthohumol (IXN) In vitro B16 (MM)
and A375
(HM)
0–100 μM The treatment of both celllines
with IXN resulted in dose-
dependent decrease of cell
viability (IC50 21.88–24.18 μM).
PI3K/Akt and MEK-ERK
signaling pathways between B16
and A375 cells were involved.
[185]
Liquiritigenin In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 equal to 97.7 μM.
NE [162]
Naringenin In vitro C32 and
A375 (HM)
ND Preliminary test determined IC50
equal to 0.6 and 13.8 μM for C32
and A375 cells, respectively.
NE [189]
In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Flavonols
Alnusin In vitro B16-BL16
(MM)
ND Preliminary test determined
IC50 > 100 μM.
NE [162]
Drabanemoroside In vitro SK-MEL-2
(HM) and
B16F1 (MM)
ND Preliminary test determined IC50
equal to 1.9 μg/ml for SK-MEL-2.
The compound was not effective
against B16F1 cells
(IC50 > 40 μg/ml).
NE [189]
Fisetin In vitro A375 (HM) 20–80 μM Preliminary test determined IC50
equal to 38.1 and 20.3 μM at 24
and 48 h after treatment.
Fisetin inhibited mTOR and
p70S6K through direct binding
while the observed inhibitory
[186]
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effect of fisetin on AKTwas
mediated indirectly, through
targeting interrelated pathways.
In vitro
and
in vivo
(mice)
A375 (HM) 10 and 20 μM, in combination
with sorafenib (2 and 5 μM)
Combination treatment (fisetin þ
sorafenib) more effectively
reduced the migration and
invasion of BRAF-mutated
melanoma cells both in vitro and
in raft cultures compared to
individual agents. In addition,
fisetin potentiated the
antiinvasive and antimetastatic
effects of sorafenib in vivo.
Combination treatment (fisetin þ
sorafenib) promoted a decrease in
N cadherin, vimentin and
fibronectin and an increase in E-
cadherin both in vitro and in
xenograft tumors. Furthermore,
combination therapy effectively
inhibited Snail1, Twist1, Slug and
ZEB1 protein expression
compared to monotherapy. The
expression of MMP-2 and MMP-9
in xenograft tumors was further
reduced in combination treatment
compared to individual agents.
[187]
In vitro
and
in vivo
(mice)
451Lu (HM) 20–100 μM (in vitro tests) and
1 and 2 mg/kg (in vivo tests)
IC50 was estimated to be 80, 37.2,
and 17.5 μM at 24, 48, and 72
hours of treatment, respectively.
A smaller average tumor volume
was consistently observed in mice
treated with fisetin. This was
more marked in animals receiving
1 mg fisetin than in animals
receiving the 2 mg dose,
indicating a nonlinear dose
response.
Fisetin decreased cell viability
with G1-phase arrest and
disruption of Wnt/β-catenin
signaling.
[188]
In vitro 451Lu and
A375 (HM)
20–80 μM The efficacy of fisetin in the
induction of apoptosis varied
with cell type as A375 cells were
more susceptible to fisetin
treatment compared to 451Lu
cells. Results confirm apoptosis as
the primary mechanism through
which fisetin inhibits melanoma
cell growth.
Fisetin treatment induced
endoplasmic reticulum (ER) stress
in highly aggressive A375 and
451Lu human melanoma cells, as
revealed by upregulation of ER
stress markers including IRE1a,
XBP1s, ATF4 and GRP78. Both
extrinsic and intrinsic apoptosis
[189]
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pathways are involved in fisetin
cytotoxic effects.
Galangin In vitro B16F10
(MM)
0–100 μM Preliminary test determined IC50
equal to 145 μM. Galangin.
Microscopical analysis revealed
the reduced number of cells and
morphological aberrations after a
24 h treatment. The appearance of
apoptotic cells such as cell
shrinking, rounding and partial
detachment was evident at a
galangin concentration of 100 μM.
Galangin activated apoptosis
signaling cascades by cleavage of
procaspase-9, procaspase-3 and
PARP in B16F10 cells. Moreover,
galangin significantly induced
activation of phosphor-p38
MAPK in a time and dose
dependent manner.
[190, 192]
In vitro
and
in vivo
(mice)
B16F10
(MM)
0–200 μM (in vitro tests) and
50 mg/kg (in vivo tests)
Galangin decreased the
proliferation of B16F10 cells in a
dose-dependent manner. The cell
viabilities were 67.9% at 50 mM
group, 54.5% at 100 mM group,
and 48.7% at 200 mM group,
respectively. A significant
reduced number of migrating
cells was observed when the cells
were treated with galangin for 24
h. In vivo models showed that
galangin inhibited lung
metastasis of B16F10 cells.
Molecular data showed that FAK
mRNA level were reduced dose-
dependently. Galangin also
reduced phosphorylation of FAK
(Tyr397) protein and suppressed
the transcription of FAK gene,
indicating FAK expression is a
candidate target of galangin.
[191]
In vitro B16 (MM) 10–250 μg/ml Preliminary test determined IC50
equal to 91.65 μg/ml.
Inhibitory effect on melanin
production and tyrosinase
activity.
[194]
Galangin-7-methyl ether In vitro B16BL6
(MM)
ND Preliminary test determined IC50
equal to 20.8 μM.
NE [175]
Icaritin In vitro A375S,
A375R,
A2058, and
MEWO (all
HM)
2.5–80 μM Preliminary test determined IC50
equal to 2.7, 6.9, 14, and 15.6 μM
in A375S, A375R, A2058, and
MEWO cells, respectively, after
72h of treatment.
Icaritin suppressed p-STAT3
(tyr705) level in parallel with
increases of p-STAT3 (ser727),
p-ERK and p-AKT. The flavonoid
significantly inhibited STAT3
nuclear translocation and reduced
[195]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
the levels of STAT3 -targeted
genes. Icaritin also inhibited IGF-
1-induced STAT3 activation
through downregulation of total
IGF-1R level.
Isorhamnetin In vitro SK-MEL-2
(HM) and
B16F1 (MM)
ND Preliminary test determined
IC50 > 40 μg/ml for both cell lines.
NE [189]
Isorhamnetin-3-O-β-D-
glucoside
In vitro SK-MEL-2
(HM) and
B16F1 (MM)
ND Preliminary test determined
IC50 > 40 μg/ml for both cell lines.
NE [189]
Kaempferol In vitro MDA-MB-
435 (HM)
1–50 μM Preliminary test determined IC50
equal to 1.5 μM.
NE [171]
In vitro SK-MEL-2
(HM)
ND Preliminary test determined IC50
equal to 6.9 μM.
NE [196]
Kaempferol-3-O-rhamnoside In vitro SK-MEL-2
(HM)
ND Preliminary test determined IC50
equal to 33.9 μM.
NE [196]
Myricetin In vitro B16F10
(MM)
3.156–50 μM Preliminary test determined IC50
equal to μM.
NE [174]
Quercetin In vitro B16F10
(MM)
3.156–50 μM Preliminary test determined
IC50 > 50 μM.
NE [174]
In vitro
and
in vivo
(mice)
B16F10
(MM)
25–50 μM (in vitro tests) and
7.5–15 mg/kg (in vivo tests), in
combination with different
doses of sulforaphane.
Quercetin and sulforaphane in
combination inhibit the
proliferation and migration of
melanoma cells more effectively
than either compound used alone.
These compounds in combination
significantly suppressed
melanoma growth as compared
to their individual use in a mouse
model.
This combined effect was
predominantly due to a decrease
in MMP 9 expression in the
mouse tumors.
[197]
In vitro
and
A375,
A2058 (HM)
0–60 μM (in vitro tests) and
100 mg/kg (in vivo tests)
Exposure to quercetin resulted in
inhibition of proliferation of
melanoma cells, induction of cell
Quercetin inhibited the activation
of STAT3 signaling by interfering
with STAT3 phosphorylation, and
[198]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
in vivo
(mice)
and B16F10
(MM)
apoptosis, and suppression of
migratory and invasive
properties. Furthermore,
quercetin suppressed A375 tumor
growth and STAT3 activities in
xenografted mice model, and
inhibited murine B16F10 cells
lung metastasis in an animal
model.
reducing STAT3 nuclear
localization.
In vitro A375,
A2058, SK-
MEL-2 and
MeWo
(HM)
0–80 μM Quercetin dose-dependently
inhibited HGF-stimulated
melanoma cell migration and
invasion.
Suppression of the HGF/c-Met
signaling pathway contributes to
the antimetastatic action of
quercetin in melanoma.
[199]
In vitro SK-MEL-2
(HM)
ND Preliminary test determined IC50
equal to 4.7 μM.
NE [194]
In vitro SK-MEL-2
(HM) and
B16F1 (MM)
ND Preliminary test determined IC50
equal to 21.1 and 8.2 μg/ml for
SK-MEL-2 and B16F1 cell lines,
respectively.
NE [189]
Quercetin-3-O-rhamnoside In vitro SK-MEL-2
(HM)
ND Preliminary test determined IC50
equal to 41.5 μM.
NE [194]
Quercetin-3-O-β-D-
glucopyranoside
In vitro SK-MEL-2
(HM) and
B16F1 (MM)
ND Preliminary test determined
IC50 > 40 μg/ml for both cell lines.
NE [189]
Rhamnetin-3-O-rhamnoside In vitro SK-MEL-2
(HM)
ND Preliminary test determined
IC50 > 100 μM.
NE [194]
Rhamnocitrin-3-O-
rhamnoside
In vitro SK-MEL-2
(HM)
ND Preliminary test determined
IC50 equal to 34.1 μM.
NE [194]
Rutin In vivo
(mice)
B16F10
(MM)
20 mg/day Rutin decreased the number of
metastatic nodules, implantation,
growth and invasion index.
NE [179]
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Flavonoid Model Cell line Concentration or dose Effectiveness Possible mechanisms of action Reference
Flavanols
Epigallocatechin In vitro CHL-1 and
WM266-4
(HM)
0.1–200 μM Preliminary test determined IC50
equal to 10.3 and 51.2 μM for
CHL-1 and WM266-4 cells.
Expression of ER stress and
apoptosis markers.
[200]
Flavanonols
Aromadendrin In vitro M14 (HM) 1–40 μM The compound was not able to
inhibit cell proliferation at 1–40
μM concentrations.
NE [166]
Pinobanksin In vitro B16BL6
(MM)
ND Preliminary test determined
IC50 > 200 μM.
NE [175]
Pinobanksin 5-methylether In vitro B16BL6
(MM)
ND Preliminary test determined
IC50 equal to 187 μM.
NE [175]
Silymarin In vitro A375-S2
(HM)
1 · 105 to 1 · 104 M It was assessed the effect of
silymarin on anti-Fas agonistic
antibody CH11 treated human
malignant melanoma, A375-S2
cells. Pretreatment with silymarin
significantly induced cell
apoptosis in CH11-treated
A375-S2 cells.
Caspase-8, 9, 3 and pan
caspase inhibitors partially
reversed silymarin induced
apoptosis of CH11-treated cells.
The expression of Fas-associated
proteins with death domain
(FADD), procaspase-8 and 3
was increased by silymarin
pretreatment.
[201]
Isoflavonoids
20-Hydroxybiochanin A In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
40-Methoxy-20,3,7-
trihydroxyisoflavanone
In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
7-O-Methylvestitol In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 24.1 μM.
NE [162]
Biochanin A In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Calycosin In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
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Daidzein In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Ferreirin In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Formononetin In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Genistein In vitro 518A2 (HM) ND Preliminary test determined
IC50 > 50 μM. The flavonoid
also reduced cell migration.
Apigenin induced an arrest of the
cell cycle of 518A2 melanoma
cells at the G2/M transition and
also attenuated the expression
and secretion of the
metastasisrelevant matrix
metalloproteinases MMP-2 and
MMP-9.
[170]
In vitro M14 (HM) 12–100 μM Genistin reduced cell
proliferation in 40.9%
at 100 μM dose.
Cytotoxic activity of genistin was
related to its antioxidant effect,
but no specific target was
investigated.
[202]
Isoangustone A (IAA) In vitro
and
in vivo
(mice)
SK-MEL-28
and SK
MEL-5
(HM)
0–20 μM (in vitro tests) and 2–
10 mg/kg (in vivo tests)
Treatment with 20 μM of IAA
inhibited the growth of SK-MEL-
28 cells up to 67% as compared
with untreated control cells.
Moreover, in a xenograft mouse
model, IAA significantly
decreased tumor growth, volume,
and weight of SK-MEL-28
xenografts.
IAA significantly blocked cell-
cycle progression at the G1-phase
and inhibited the expression of
G1-phase regulatory proteins,
including cyclins D1 and E in the
SK-MEL-28 cell line. IAA
suppressed the phosphorylation
of Akt, GSK-3b, and JNK1/2. IAA
also bound to phosphoinositide 3-
kinase (PI3K), MKK4, and MKK7,
strongly inhibiting their kinase
activities in an ATP-competitive
manner.
[203]
Isovestitol In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 equal to 33.6 μM.
NE [162]
Mucronulatol In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 30.4 μM.
NE [162]
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Pratensein In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Vestitol In vitro B16-BL6
(MM)
ND Preliminary test determined IC50
equal to 57.4 μM.
NE [162]
Vestitone In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Violanone In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 >100 μM.
NE [162]
Xenognosin B In vitro B16-BL6
(MM)
ND Preliminary test determined
IC50 equal to 34.1 μM.
NE [162]
ND: not described; NE: not evaluated; HM: human melanoma cell line; MM: murine melanoma cell line.
Box 1. Anticancer activity of flavonoids on melanoma cell lines.
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apigenin in an experimental lung metastasis model. Apigenin-treated mice had significant fewer
metastatic nodules when compared to the vehicle control group, suggesting apigenin inhibits the
metastasis potential of B16F10 melanoma cells in vivo mouse model (Figure 4).
6.2. Bioactivity of diosmin on melanoma
Diosmin is a glycosylated flavonoid commonly used as an active constituent of several
pharmaceutical products, mainly for cardiovascular diseases treatment. Diosmin is used in
the treatment of venous insufficiency, because of its vasoprotector and venotonic properties.
In addition, it acts as an antioxidant, anti-inflammatory, and antimutagenic molecule, regu-
lating the activity of several enzymes, including cyclooxygenases and cytochrome P450 pro-
teins [177, 179]. Interestingly, the anticancer effects of diosmin have also been studied
[176, 178], suggesting that this flavonoid presents a broad spectrum of pharmacological
activities.
Conesa et al. [179] performed a comparative study with three different flavonoids (tangeretin,
rutin, and diosmin) using an experimental model of B16F10 melanoma cell-induced pulmo-
nary metastasis. The greatest reduction in the number of metastatic nodules (52%) was obtained
with diosmin treatment. Similarly, diosmin presented a relevant decreasing in implantation,
growth, and invasion index (79.40, 67.44, and 45.23%, respectively). These results were confirmed
by another study developed by Martínez et al. [178], suggesting diosmin is an effective agent
against metastatic stages of melanoma.
The antimetastatic effect of diosmin has also been evaluated in combination with IFN-α
[176, 177], an important cytokine that has shown the significant effect in the treatment of
metastatic melanoma in high doses. In both investigations, it was verified that synergistic
antiproliferative and antimetastatic effects shown by the combination of the flavonoid and
the lowest dose of IFN-α, which was similar to that produced by the highest dose of the
cytokine alone. These results suggest that diosmin may be used in combination with IFN-α in
an attempt to reduce its therapeutic dose, thereby reducing the side effects promoted by
continued cytokine use.
Figure 4. Apigenin inhibited murine melanoma B16F10 cell lung metastasis. B16F10 melanoma cells were injected into
the tail vein of the C57BL/6 mice. These mice then received intragastric administration of vehicle or apigenin (150 mg/kg/
day) for 24 consecutive days. Lung metastasis of B16F10 melanoma cells in the mouse model (upper) and the metastasis
nodules number in the lungs (bottom) were shown. Data were mean  SD, n = 8, *p < 0.05. This figure was taken from Ref.
[172].
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6.3. Bioactivity of fisetin on melanoma
Fisetin (3,7,30,40-tetrahydroxyflavone) is a flavonol also found inmany fruits and vegetables, such
as strawberries, apples, persimmons, kiwi, onions, and cucumbers. This flavonoid has shown a
relevant neuroprotective effect, aiding in memory and cognition processes, as well as reducing
behavioral deficits. Recently, the effect of fisetin on anticancer therapy has also been studied [186].
Investigation conducted by Syed et al. [188] determined an IC50 value of 38.1 and 20.3 μM
against A375 human melanoma cell line, at 24 and 48 h after treatment. In a subsequent study,
Syed et al. [191] have demonstrated that fisetin induces apoptosis in melanoma cells. The
efficacy of fisetin in the induction of apoptosis varied with cell type and preliminary results
confirmed apoptosis as the primary mechanism through which fisetin inhibits melanoma cell
growth. The possible mechanisms involved include upregulation of ER stress markers such as
IRE1a, XBP1s, ATF4, and GRP78. In addition, both extrinsic and intrinsic apoptosis pathways
are involved in fisetin cytotoxic effects.
The effect of fisetinwas also evaluated on the growth ofmetastatic 451Lu humanmelanoma cells,
which exhibit constitutiveWnt signaling inaddition toharboringamutation in theB-Rafgene.The
IC50 valuewas estimated to be 17.5μMat 72 h of treatment in theMTTassay. In an in vivomodel, a
smaller average tumor volume was consistently observed in mice treated with fisetin. This was
moremarked in animals receiving 1mg fisetin than in animals receiving the 2mgdose, indicating
a nonlinear dose response. The authors attributed this effect to a decreasing of cell viability with
G1-phase arrest and disruption ofWnt/β-catenin signalingmediated by fisetin [186].
A recent report evaluated the effect of fisetin in combination with sorafenib, a multi-kinase
inhibitor of mutant and wild-type BRAF and CRAF kinases, on melanoma cell invasion and
metastasis. In this study, fisetin potentiated the anti-invasive and antimetastatic effects of
sorafenib in vivo, suggesting that this flavonoid can be used as an alternative agent in mela-
noma therapy reducing doses of anticancer drugs used for this purpose [187].
6.4. Bioactivity of luteolin on melanoma
Luteolin is a common flavone that exists in many types of plants including fruits, vegetables,
and medicinal herbs. This flavonoid presents potential for cancer prevention and therapy
[174]. Concerning to melanoma treatment, George et al. [182] showed that luteolin possesses
relevant cytotoxicity against A375 human melanoma cell line, with an IC50 value of 115.1 μM
in a preliminary test. Luteolin also inhibited colony formation and induced apoptosis in a dose
and time-dependent manner by disturbing cellular integrity. Accumulation of cells in the G0/
G1 (60.4–72.6%) phase for A375 cells after 24 h treatment indicated cell cycle arresting potential
of this flavonoid, suggesting that luteolin inhibits cell proliferation and promotes cell cycle
arrest and apoptosis in human melanoma cells. A similar result was demonstrated by
Casagrande and Darbon [204], who highlighted the involvement of the regulation of cyclin-
dependent kinases CDK2 and CDK1 in the antiproliferative effect of luteolin on OCM-1
human melanoma cells.
In a recent investigation, the inhibitory effect of luteolin on melanoma cell proliferation was related
to ER stress induced. In this context, luteolin increased the expression of the ER stress-related
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proteins, such as protein kinase RNA-like ER kinase, phosphorylation eukaryotic translation
initiation factor 2α, activating transcription factor (ATF) 6, CCAAT/enhancer-binding protein-
homologous protein (CHOP), and cleaved caspase 12. In addition, luteolin increased the level of
intracellular ROS, leading to ROS-mediated apoptosis and ER stress, suggesting that luteolin
induces apoptosis by ER stress via increasing ROS levels [183].
Anticancer potential of luteolin has also evaluated in vivo. In experimental metastasis model,
mice treatment with luteolin (10 or 20 mg/kg) reduced metastatic colonization in the lungs by
50%. This treatment increased E-cadherin expression while reduced the expression of vimentin
and β3 integrin in the tumor tissues [184]. These results encourage the use of luteolin as an
anticancer chemopreventive and chemotherapeutic agent.
6.5. Bioactivity of quercetin on melanoma
Quercetin is a noncarcinogenic dietary flavonoid with low toxicity, has been shown to exert
antioxidant, anti-inflammatory, neuroprotective, and antimelanoma activities [193]. A prelim-
inary study showed that quercetin presents a weak cytotoxic effect on B16F10 murine mela-
noma cells, with an IC50 value > 50 μM [174]. However, Casagrande and Darbon [204] and Kim
et al. [196] showed that quercetin presents a considerable antiproliferative effect on OCM-1
and SK-MEL-2 human melanoma cells, with an IC50 value between 4.7 and 19 μM. In these
investigations, the authors demonstrated that the presence of hydroxyl group at the 30-position
of the ring B in quercetin favors the cytotoxic effect and a G1 cell cycle arrest. The involvement
of the regulation of cyclin-dependent kinases CDK2 and CDK1 may also be present in its
anticancer effect.
Cao et al. [198] evaluated the involvement of STAT3 signaling in the inhibitory effects of
quercetin on melanoma cell growth, migration, and invasion. Quercetin treatment promoted
inhibition in proliferation of melanoma cells, induction of cell apoptosis, and suppression of
migratory and invasive properties. Furthermore, mechanistic study indicated that quercetin
inhibits the activation of STAT3 signaling by interfering with STAT3 phosphorylation, and
reducing STAT3 nuclear localization. In an animal model, quercetin inhibited murine B16F10
cells lung metastasis, indicating that quercetin possesses antitumor potential.
7. Brief structure-activity relationship (SAR) considerations
Nagao et al. [167] evaluated the cytotoxic activity of 21 flavones and the effect of the substitu-
tion patterns on their anticancer potential, although the authors highlight that the number of
compounds examined might not be sufficient to determine the structure-activity relationships.
Generally, the data show that the growth inhibitory activity of one flavone against the three
different tumor cell lines (including a murine melanoma cell line) is not always the same,
suggesting differences in the sensitivity of tumor cells to flavones.
The influences of ring A substituents against B16F10 cells were examined. Comparing the
antiproliferative activity of four 30,40-di-OH-flavones, the order of contribution was found to
be 5-OH-6,7-di-OCH3 > 5,6,7-tri-OH > 5,7-di-OH-6-OCH3 > 5,7-di-OH. In contrast, in the
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30-OH-40-OCH3-flavones (desmethoxycentaureidin, eupatorin, and 5,6,30-trihydroxy-7,40-
dimethoxyflavone), the order is 5,6-di-OH-7-OCH3 > 5-OH-6,7-di-OCH3 > 5,7-di-OH-6-OCH3.
In the 30,40-di-OCH3-flavones (eupatilin and 5,6-dihydroxy-7,30,40-trimethoxyflavone), the order
is 5,6-di-OH-7-OCH3 > 5,7-di-OH-6-OCH3, and in the 30-OCH3-40-OH-flavones (jaceosidin and
cirsilineol), it is 5,7-di-OH-6-OCH3 > 5-OH-6,7-di-OCH3. In addition, for ring B substituents, 30,40-
di-OH and 30,40-di-OH-50-OCH3 showed a greater effect than the others, but the influence of 30,50-
di-OCH3-40-OH appears to be not relevant [167].
Another investigation evaluated the effects of polyhydroxylated flavonoids on the growth of
B16F10 melanoma cells. In general, the results suggest that the presence of a C2–C3 double bond
and three adjacent hydroxyl groups in the A- or B-rings confers greater antiproliferative activity
[174]. Casagrande and Darbon [204] investigated the effects of a series of flavonoids on cell
proliferation and cell cycle distribution in human melanoma cells (OCM-1). Interestingly, the
presence of a hydroxyl group at the 30-position of the ring B in quercetin and luteolin was
correlated to a G1 cell cycle arrest while its absence in kaempferol and apigenin was correlated to
a G2 block.
The presence of isoprenoid units in the cytotoxic effect of flavonoids has also been evaluated for
melanoma cells [168]. The results indicated that isoprenoid substitutions in flavonoids enhance
their cytotoxic potential, and that the position of attachment and the number of isoprenoid-
substituent moieties per molecule influence flavonoid cytotoxicity. This is probably related to
their lipophilicity and affinity properties, which favor penetration into the cell membrane.
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